ClinicalTrials.gov
public full text
Public Domain
Niraparib In Recurrent IDH 1/2 Gliomas
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. \- This research study involves an experimental treatment called Niraparib.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of Abemaciclib in Recurrent Glioblastoma#854304
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease#1074880
- Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma#879144
- Editorial: Innovative approaches in glioma therapy: exploring new therapeutic frontiers, volume II#438735
- Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)#1140651
Record · ID 835235
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive